Elizabeth Holmes Documentary Opens to $15 Million on a Narrow Screen Count
A three-hour documentary built around Elizabeth Holmes and the collapse of Theranos has delivered one of the strongest nonfiction launches in recent memory, taking in $15 million in North America on its debut weekend despite playing on just 855 screens across the United States and Canada. The opening places You Can See Everything behind only Paramount’s new video game adaptation Street Fighter at the box office, and it gives the film an early commercial result that far outstrips what most documentaries can achieve in wide release.
The performance is even more striking because of the film’s constraints. A runtime of three hours limits the number of daily showings, yet audiences still turned it into the second-best opening ever for a non-music documentary, trailing only Michael Moore’s Fahrenheit 9/11 from 2004. For a nonfiction title playing on fewer than 1,000 screens, the debut also ranks as the largest since Borat in 2006. In box office terms, those figures place the film in rare company.
The box office numbers are doing more than rewarding curiosity; they are extending the public appetite for the Theranos story into a new format.
Holmes, Fielder and the Mechanics of a Public Unraveling
You Can See Everything was filmed largely in 2023, during the month before Holmes began her 11-year prison sentence. The documentary places viewers inside her California home, where Holmes and her partner Billy Evans allowed a skeptical film crew to document their lives 34 days before her incarceration. Co-director Nathan Fielder, whose work has repeatedly blurred the line between documentary, social experiment and performance art, inserts himself into the action and becomes part of the film’s tension rather than a distant observer.
That approach matters because the subject at the center of the film is not just a fallen founder, but one of the most recognizable figures from the Theranos scandal. Holmes was convicted of defrauding investors in her medical testing company, a case that has already generated books, podcasts and the mini-series The Dropout, which starred Amanda Seyfried. The new documentary enters a story that has been heavily mined already, yet the trailer and premiere suggest the film found fresh momentum by turning the process of observation itself into the drama.
There is a sharp irony at the heart of the project: a woman convicted in a case involving deceptive claims about medical testing allows cameras into her private world while insisting on her version of events.
Viral Teaser, Reenactments and Awards-Season Heat
The film’s first teaser arrived shortly after its surprise premiere at the Telluride Film Festival in Colorado and quickly spread online, helped by a widely shared clip of Holmes staring unblinkingly at Fielder and asking, “Why would I deceive you?” The line landed because it condensed the entire public memory of Theranos into one surreal exchange. It also fed the online meme cycle that now surrounds the film, where skepticism and fascination appear to be reinforcing each other rather than competing.
Seyfried appears in the hybrid documentary to reenact events and scenes the production team could not capture or needed to reconstruct. That choice pushes the film further away from conventional documentary form and closer to a staged meditation on truth, memory and image control. For audiences already familiar with Holmes, the reenactments do not simply fill gaps; they underline how much of the story has always depended on presentation, performance and the audience’s willingness to believe.
Reviews have amplified that effect. The Guardian called the film “a modern masterpiece of deceit,” while The Financial Times described it as “a mind-bending revelation.” The New York Times framed the film as a contest in which Holmes and Fielder “joust in a dizzying movie about truth, reality and the contours of knowledge.” Those responses help explain why awards chatter began almost immediately after the Telluride debut.
Box Office Momentum and the Documentary Exception
Documentaries rarely generate this kind of theatrical heat, particularly in a market where nonfiction titles often depend on festivals, streaming platforms or specialty runs. A $15 million opening on 855 screens is not simply a good documentary result; it is a market anomaly. The film’s scale, running time and subject matter would normally work against broad commercial appeal, yet the opposite happened. Curious viewers, festival buzz and the long-standing fascination with Holmes converged to produce a debut that looks more like a prestige narrative launch than a conventional documentary rollout.
The film’s numbers also point to a particular kind of cultural relevance. Holmes remains a figure whose name still carries immediate recognition because the Theranos case linked Silicon Valley ambition, investor fraud and medical technology in one highly public collapse. Even without adding new facts to the underlying case, the documentary taps into a story that still resonates because it sits at the intersection of healthcare trust, corporate deception and public spectacle.
Awards Prospects and the Limits of the Hype Cycle
Industry chatter is already positioning You Can See Everything as a contender for best documentary feature at next year’s Academy Awards. No documentary has ever been nominated for the main best picture prize, and the film’s momentum is more likely to translate into documentary recognition than a breakthrough in the top category. The likely path is narrower than some of the online excitement suggests, even if the opening weekend gives the film immediate leverage in awards-season conversation.
The UK release, scheduled for 20 November, will offer another test of whether the film’s appeal is driven primarily by American fascination with Holmes or by broader interest in the way the documentary reframes an already notorious public figure. For now, the commercial debut has done something unusual: it has turned a story about fraud, performance and image management into one of the year’s biggest nonfiction box office events. The film’s next challenge is whether that early surge holds once the novelty fades and the conversation shifts from viral clips to sustained audience demand.